Lausanne-headquartered Hedera Dx is pioneering the adoption of liquid biopsy in cancer treatments. The biotech startup has just raised €14 million to push forward its mission of bringing better access to cutting-edge treatments to patients around the world. Cancer. One of the world’s most prevalent and devastating illnesses, it’s reported that 1 in 3 people…
This content is for members only. Visit the site and log in/register to read.
The post Swiss biotech startup Hedera Dx raises €14 million in its mission to improve cancer treatment options appeared first on EU-Startups.